Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin

Background. In patients with chronic renal disease, other lipid markers than total cholesterol or low density lipoprotein (LDL)-cholesterol are probably more appropriate to detect a potential lipid-related risk for progression to renal failure. Statin therapy might be protective. Methods. From 1999...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nephrology, dialysis, transplantation dialysis, transplantation, 2007-06, Vol.22 (6), p.1578-1586
Hauptverfasser:	Ozsoy, Riza C., van der Steeg, Wim A., Kastelein, John J. P., Arisz, Lambertus, Koopman, Marion G.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Anticholesteremic Agents - pharmacology apolipoprotein B atorvastatin Atorvastatin Calcium Biological and medical sciences chronic kidney disease Cohort Studies Disease Progression dyslipidaemia Dyslipidemias - diagnosis Emergency and intensive care: renal failure. Dialysis management Female Heptanoic Acids - pharmacology Humans Intensive care medicine Kidney Failure, Chronic - diagnosis Kidney Failure, Chronic - drug therapy Male Medical sciences Middle Aged Nephrology. Urinary tract diseases Nephropathies. Renovascular diseases. Renal failure Predictive Value of Tests Prospective Studies proteinuria Pyrroles - pharmacology Renal failure Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Surgery of the urinary system
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!